尿激酶在原发性肾病综合征治疗中的价值初探

Value of urokinase in treating patients with nephrotic syndrome

目的探讨尿激酶在原发性肾病综合征治疗中的作用。方法根据血浆中D-二聚体(D-D)水平,将临床确诊为肾病综合征的患者分为2组,试验组(A组)除常规应用低分子肝素外加用尿激酶治疗,对照组(B组)常规应用低分子肝素,两组均规律口服强的松治疗,观察两组的治疗效果。结果 A组患者总有效率高于B组(P<0.05);在治疗有效人群中,两组起效时间比较,差异无统计学意义(P=0.08)。结论 D-D作为体内高凝状态和纤溶亢进的分子标记物之一,尿激酶作为溶栓的主要药物,在肾病综合征的治疗中具有重要的指导意义。

Objective To investigate the value of urokinase in treating patients with nephrotic syndrome.Methods According to the different levels of D-dimer in plasma,the patients with nephrotic syndrome were divided into two groups.Treatment group（group A）used low molecular heparin combined with urokinase;control group（group B）regularly used low molecular heparin.Patients of the two groups all took prednisone orally,and the efficacy of the two groups were observed.Results There was significant difference in effective rate between the two groups（P0.05）.In the effective population,there was no significant difference in effective time between the two groups（P=0.08）.Conclusion As one of the molecular marker in the coagulation and hyperfibrinolysis D-dimer and urokinase（main drug for treating thrombolysis） play an important role in the treatment for nephritic syndrome.